CliffBio
small molecule

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

Loss of exclusivity—loss of exclusivity
CompanyAlcon →See this company's full patent-cliff portfolio

Drug detail

Brand nameNEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE
Active ingredientDEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Strength0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML
Dosage formSUSPENSION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalNovember 1986
Marketing statusDISCN

More from Alcon

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE patent cliff — loss of exclusivity — | CliffBio